Ribociclib in Treating Patients With Advanced Neuroendocrine Tumors of Foregut Origin

NCT02420691 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

21

Enrollment

OTHER

Sponsor class

Conditions

Advanced Digestive System Neuroendocrine Neoplasm
Duodenal Neuroendocrine Tumor G1
Functional Pancreatic Neuroendocrine Tumor
Gastric Neuroendocrine Tumor
Intermediate Grade Lung Neuroendocrine Neoplasm
Low Grade Lung Neuroendocrine Neoplasm
Nonfunctional Pancreatic Neuroendocrine Tumor
Thymus Neoplasm

Interventions

OTHER: Laboratory Biomarker Analysis
OTHER: Pharmacological Study
DRUG: Ribociclib

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]
[object Object]